Here, we aim to provide an up-to-date review of the current state of knowledge of HER2-low and HER2-ultralow breast cancer, including the biological and clinical, as well as present current challenges in histological diagnosis with recent advances in quantifying HER2 expression such as the use of artificial intelligence and mRNA assays. This evidence concerns the gene ERBB2 and breast carcinoma.